Treatment of Pruritus in Hepatic Cirrhosis

Introduction to Therapeutic Approach

The British Society of Gastroenterology recommends rifampicin as a first-line treatment for cholestatic pruritus in hepatic cirrhosis, with cholestyramine as an alternative first-line option due to its safety profile 1, 2

The European Association for the Study of the Liver suggests starting rifampicin at 150 mg twice daily, increasing progressively up to 600 mg twice daily if necessary, with mandatory liver monitoring 1
Meta-analyses demonstrate superior efficacy for reducing hepatic pruritus compared to placebo, with a strength of evidence rated as high 3, 4
The American Association for the Study of Liver Diseases recommends informing patients about the change in color of secretions when using rifampicin 1
Cholestyramine (4-16 g per day in divided doses) is an alternative first-line option, with a favorable safety profile justifying its frequent use despite limited evidence of efficacy, and should be administered separately from other medications 2, 5, 6

The American Gastroenterological Association recommends sertraline 75-100 mg per day as a second-line treatment, acting on central nervous system neurotransmitters, with demonstrated efficacy in controlled trials for cholestatic pruritus 1, 2, 3, 4
Patients should be warned about dry mouth when using sertraline 2

The European Society of Gastrointestinal Endoscopy suggests naltrexone or nalmefene as third-line options, with naltrexone 50 mg per day orally, and demonstrated efficacy in randomized controlled trials for cholestatic pruritus, but with significant side effects and tolerance issues 1, 2, 3, 4

The American Association for the Study of Liver Diseases recommends bezafibrate specifically for sclerosing cholangitis and applicable to other cholestases, with a strength of evidence rated as moderate 7
Experimental agents, including dronabinol, phenobarbital, propofol, and topical tacrolimus, may be considered, with a strength of evidence rated as low 1, 8

The American Association for the Study of Liver Diseases suggests ursodeoxycholic acid (10-20 mg/kg/day) may improve pruritus in 67-80% of patients, but is not generally considered a first-line treatment due to limited evidence, with a strength of evidence rated as low 9, 8
High doses of ursodeoxycholic acid (28-30 mg/kg/day) are contraindicated 7

The European Association for the Study of the Liver recommends excluding significant bile duct stenoses as a cause of progressive pruritus, and treating with balloon dilation if present and accessible, with a strength of evidence rated as moderate 7
Bezafibrate or rifampicin is recommended for moderate to severe pruritus, with a strength of evidence rated as moderate 7

The American Gastroenterological Association advises against using gabapentin for hepatic pruritus, as a controlled trial showed no benefit compared to placebo, with a strength of evidence rated as high 1, 10, 2
Antihistamines have limited efficacy, but may be useful as adjuncts, with a strength of evidence rated as low 2
Long-term use of sedating antihistamines may predispose to dementia and should be avoided except in palliative care, with a strength of evidence rated as moderate 10

The British Society of Gastroenterology recommends UVB phototherapy as an effective option for many patients with cholestatic pruritus, with a strength of evidence rated as moderate 1, 10
Nasobiliary drainage provides transient relief but is technically complicated, difficult to tolerate, and carries a risk of pancreatitis, with a strength of evidence rated as low 2
Plasmapheresis or albumin exchange provides temporary relief in extreme situations, with a strength of evidence rated as low 2
Liver transplantation is highly effective, with rapid reduction of pruritus (often within the first 24 hours), and is indicated for "persistent and refractory" pruritus after therapeutic trials, with a strength of evidence rated as high 2